Pityriasis rosea in chronic hepatitis C.

Pityriasis rosea associated with pegylated interferon alfa and ribavirin treatment in a patient with chronic hepatitis C.

BACKGROUND Pityriasis rosea is an acute inflamatory skin disease that the etiology is unknown but some viral agents like human herpes virus-6 and 7 and drugs are suspected. CASE REPORT A-58-year-old man with chronic hepatitis C was being followed up in our hospital. Pegylated interferon (PEG-IFN) alfa-2b (100 μg per week) and ribavirin (1000 mg/day) was started. In the third month of this tre...

Pityriasis rosea in a patient with retrovirus infection and a history of syphilis and positive results of infection with hepatitis A virus, hepatitis B virus and hepatitis C virus

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)

Imatinib mesylate (Gleevec™, STI571), a selective inhibitor of BCR-ABL, c-Kit, and platelet-derived factor receptor, has been used to treat chronic myelogenous leukemia (CML) and gastrointestinal stromal tumors. Although its use has been associated with various adverse cutaneous reactions, pityriasis rosea-like drug eruptions are rare. Here, we report a case of pityriasis rosea-like drug erupti...

Pityriasis rosea in pregnancy: report of a spousal occurrence and craniosynostosis in the healthy newborn

BACKGROUND Pityriasis rosea is a papulosquamous disease. It may occur during pregnancy; in this setting, it has occasionally been associated with adverse outcomes. PURPOSE A woman who developed pityriasis rosea at the beginning of her eighth week of gestation is described. The outcomes in newborns delivered by pregnant women who developed pityriasis rosea during gestation are summarized. ME...

A Case-Control Study on the Take-Off Sign in Lesional Skin Biopsies of Patients with Pityriasis Rosea

Dear Editor-in-Chief   Lesional histopathological features in pityriasis rosea (PR) are non-specific (1).  Our aim here is to investigate whether a histopathological take-off sign (TOS) is associated with PR.